Table 2.
Study | N (at 12 months follow‐up) | Overall pain at baseline | Overall pain at 12 months | Responder rates |
---|---|---|---|---|
Causalgia | ||||
Liem et al.27 | 4 | 7.3 ± 1.0 | 4.0 ± 3.4 | |
Deer et al.23 | 25 | 7.3 ± 2.0 | 1.9 ± 2.3 | |
Morgalla et al.28 | 25 | 8.4 ± 1.0 | 3.8 ± 1.1 | |
Morgalla et al.29 | 40 | 8.3 ± 0.9 | 4.0 ± 0.82 | |
Huygen et al.24 | 10 | 7.0 ± 1.6 | 4.0 ± 2.5 | |
104 | 8.0 ± 1.2* | 3.4 ± 1.5* | 68% | |
CRPS‐I | ||||
Liem et al.27 | 7 | 7.7 ± 1.0 | 2.7 ± 3.3 | |
Deer et al.23 | 30 | 7.6 ± 1.4 | 2.2 ± 2.3 | |
Huygen et al.24 | 9 | 7.8 ± 1.7 | 5.0 ± 2.8 | |
46 | 7.7 ± 1.4* | 2.8 ± 2.6* | 71% | |
FBSS and CLBP | ||||
Liem et al.27 | 8 | 8.2 ± 0.97 | 4.8 ± 3.2 | |
Huygen et al.24 | 22 | 7.3 ± 2.6 | 4.5 ± 2.7 | |
Kallewaard et al.25 | 14 | 7.0 ± 1.4 | 2.3 ± 2.1 | |
Kallewaard et al.26 | 9 | 7.9 ± 1.1 | 2.4 ± 2.9 | |
53 | 7.5 ± 1.8* | 3.6 ± 2.8* | 55% |
Weighted mean and standard deviation.